NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma

Journal of Hepatology

Volumn 45, Issue 1, 2006, Pages 81-89

  Macheiner, Doris ^a   Heller, Gerwin ^b   Kappel, Sonja ^b   Bichler, Christoph ^a   Stättner, Stefan ^c   Ziegler, Barbara ^b   Kandioler, Daniela ^b   Wrba, Fritz ^b   Schulte Hermann, Rolf ^a   Zöchbauer Müller, Sabine ^b   Grasl Kraupp, Bettina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Epigenetic gene silencing; Human hepatocellular carcinoma; NORE1B; RASSF1A

Indexed keywords

NORE 1A PROTEIN; NORE 1B PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOMA CELL; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLOBINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; POLYMERASE CHAIN REACTION;

EID: 33744937935     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.12.017     Document Type: Article

References (37)

1. Xavier F., Ribes J., Diaz M., and Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing liver tumor cells-a mechanism of immune evasion?. Nat Med 2 (1996) 1361-1366
4. Grisham J.W. Molecular genetic alterations in primary hepatocellular neoplasms. In: Coleman W.B., and Tsongalis G.J. (Eds). The molecular basis of human cancer: molecular genetic alterations in primary hepatocellular neoplasms (2002), Humana Press, Totowa 269-346
5. Coleman M.L., Marshall C.J., and Olson M.F. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5 (2004) 355-366
6. Cox A.D., and Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 22 (2003) 8999-9006
7. Shivakumar L., Minna J., Sakakami T., Pestell R., and White M.A. The Rassf1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22 (2002) 4309-4318
8. Agathanggelou A., Cooper W.N., and Latif F. Role of the ras-associated domain family 1 tumor suppressor gene in human cancers. Cancer Res 65 (2005) 3497-3508
9. Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., et al. The tumor suppressor RASSF1A regulates mitosis by inhibiting the APC-CdC20 complex. Nat Cell Biol 6 (2004) 129-137
10. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., and Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25 (2000) 315-319
11. Burbee D.G., Forgacs E., Zöchbauer-Müller S., Shivakumar L., Fong K., Gao B., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93 (2001) 691-699
12. Ortiz-Vega S., Khokhlatchev A., Nedwidek M., Zhang X.F., Dammann R., Pfeifer G.P., et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21 (2002) 1381-1390
13. Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., et al. Identification of a novel ras-regulated proapoptotic pathway. Curr Biol 12 (2002) 253-265
14. Aoyama Y., Avruch J., and Zhang X.F. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 23 (2004) 3426-3433
15. Vos D.M., Martinez A., Ellis C.A., Vallecorsa T., and Clark G.J. The pro-apoptotic ras effector NORE1 serves as a ras-regulated tumor suppressor in the lung. J Biol Chem 278 (2003) 21938-21943
16. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
17. Hesson L., Dallol A., Minna J.D., Maher E.R., and Latif F. Nore1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22 (2003) 947-954
18. Kok K., Naylor S.L., and Buys C.H. Deletions of the short arm of chromsome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71 (1997) 27-92
19. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J., and Kang G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163 (2003) 1371-1378
20. Schagdarsurengin U., Wilkens L., Steinemann D., Flemming P., Kreipe H.H., Pfeifer G.P., et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22 (2003) 1866-1871
21. Raidl M., Pirker C., Schulte-Hermann R., Aubele M., Kandioler-Eckersberger D., Wrba F., et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol 40 (2004) 660-668
22. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48.000 necropsies. Cancer 7 (1954) 462-503
23. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 22 (1995) 983-993
24. Raidl M., Berger W., Schulte-Hermann R., Kandioler-Eckersberger D., Kappel S., Wrba F., et al. Expression of the lung restistance-related protein (LRP) in human and rat hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol 283 (2002) G1117-G1124
25. Humphries S.E., Gudnason V., Whitall R., and Day I.N.M. Single-strand conformational polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterinemia. Clin Chem 43 (1997) 427-435
26. Biéche I., Olivi M., Chempéme M.H., Vidaud D., Lidereau R., and Vidaud M. Novel approach to quantitate polymerase chain reaction using real time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 78 (1998) 661-666
27. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
28. Li L.C., and Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18 (2002) 1427-1431
29. Oka M., Meacham A.M., Hamazaki T., Rodic N., Chang L.J., and Terada N. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2′-deoxycytidine. Oncogene 19 (2005) 3091-3099
30. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 11 (2005) 4727-4741
31. Sun L., Hui A.M., Kanai Y., Sakmoto M., and Hirohashi S. Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 88 (1997) 1165-1170
32. Li J., Wang F., Protopopov A., Malyukova A., Kashuba V., Minna J.D., et al. Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene. Oncogene 23 (2004) 5941-5949
33. Dallol A., Agathanggelou A., Fenton S.L., Ahmed-Choudhury J., Hesson L., Vos M.D., et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64 (2004) 4112-4116
34. Crespo P., and Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 57 (2000) 1613-1636
35. Jagirdar J., Nonomura A., Patil J., Thor A., and Paronetto F. Ras oncogene p21 expression in hepatocellular carcinoma. J Exp Pathol 4 (1989) 37-46
36. Tiniakos D., Spandidos D.A., Kakkanas A., Pintzas A., Pollice L., and Tiniakos G. Expression of ras and myc oncogenes in hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res 9 (1989) 715-721
37. Dammann R., Schagdarsurengin U., Seidel C., Strunnikova M., Rastetter M., Baier K., et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20 (2005) 645-663